TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05775822

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan and blood sample collection
Description: Each enrolled patient performs:~* preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~* a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~* CT scan
Study: NCT04918641

Intervention type: OTHER
Intervention: assessment
Description: Physical, developmental, neurological, behavioral, and neurocognitive assessments
Study: NCT03091413

Intervention type: DIAGNOSTIC_TEST
Intervention: diaphragm ultrasound
Description: For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient.
Study: NCT06510036

Intervention type: OTHER
Intervention: The post-processing generated after scanning is converted into energy spectrum image data (SBI)
Description: It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.

Intervention type: OTHER
Intervention: The post-processing generated after scanning is converted into energy spectrum image data (SBI)
Description: It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.
Study: NCT05269004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
Study: NCT05357040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide gas for inhalation
Description: 60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT06552715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of resorbable HAp-based composite
Description: The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.
Study: NCT04876703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multichannel Functional electrical stimulation
Description: The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard motor training
Description: Standard motor training is the conventional rehabilitation treatment
Study: NCT05598294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization recommendations
Description: Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
Study: NCT05175937

Intervention type: DEVICE
Intervention: smartphone APP based remote monitoring
Description: smartphone APP to monitor remotely patients implanted with ICD

Intervention type: DEVICE
Intervention: bedside transmitter based remote monitoring
Description: bedside transmitter to monitor remotely patients implanted with ICD
Study: NCT05582265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab（neoadjuvant）
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab（neoadjuvant）
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin （neoadjuvant）
Description: Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin （neoadjuvant）
Description: Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel （neoadjuvant）
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel （neoadjuvant）
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Standard of care
Study: NCT05062356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 15mg
Study: NCT05582265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Standard of care

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical resection
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin（adjuvant）
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin（adjuvant）
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin（adjuvant）
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab（adjuvant）
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab（adjuvant）
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Recommended, standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Recommended, standard of care

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Recommended, standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (neoadjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (neoadjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (adjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (adjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin (adjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT05310513

Intervention type: OTHER
Intervention: Whether the patient needs to be admitted to the ICU
Description: According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.

Intervention type: OTHER
Intervention: Whether the patient needs to be admitted to the ICU
Description: According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.
Study: NCT06041373

Intervention type: DEVICE
Intervention: Verily Watch Cardio
Description: The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.

Intervention type: DEVICE
Intervention: iRhythm Zio monitor
Description: The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.

Intervention type: DEVICE
Intervention: Schiller CARDIOVIT FT-1
Description: The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
Study: NCT03454646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)
Description: The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
Study: NCT05622136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib Oral Product
Description: Dose escalation strategy
Study: NCT05692284

Intervention type: OTHER
Group type: OTHER
Intervention: routine care group
Description: Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care in accordance with Orem's theory group
Description: Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
Study: NCT06122233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Fibrosis self-management package and smartphone application
Description: The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources.
Study: NCT05568979

Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine
Description: Intramuscular or subcutaneous administration

Intervention type: BIOLOGICAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: Intramuscular administration
Study: NCT05182619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided stellate ganglion block
Description: under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided stellate ganglion block
Description: under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
Study: NCT05357040

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT05185843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study: NCT06121895

Intervention type: OTHER
Intervention: Video Laryngeal Mask
Description: Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.

Intervention type: OTHER
Intervention: Fastrack Laryngeal Mask
Description: Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
Study: NCT06087042

Intervention type: DIAGNOSTIC_TEST
Intervention: serum and unstimulated salivary samples
Description: Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC

Intervention type: DIAGNOSTIC_TEST
Intervention: serum and unstimulated salivary samples
Description: Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC

Intervention type: DIAGNOSTIC_TEST
Intervention: serum and unstimulated salivary samples
Description: Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC
Study: NCT06191666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based education and discussion
Description: Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual 1:1 counseling
Description: Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based behavioral skills development and cooking demonstrations
Description: Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfitBwell
Description: This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
Study: NCT05470517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-peritoneal Fluid Aspiration
Description: Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-peritoneal Fluid Aspiration
Description: Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
Study: NCT06357234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
Study: NCT05702515

Intervention type: OTHER
Intervention: Digital ECG Data Collection
Description: synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure